Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 9/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 9/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 9/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076593 | 0.88 | L3MBTL1 (0.57) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL1418850 | 0.85 | L3MBTL1 (0.40) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL2260731 | 0.81 | L3MBTL1 (0.51) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL5201283 | 0.80 | L3MBTL1 (0.54) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL50031 | 0.78 | HSD17B10 (0.57) | L3MBTL1CYP3A4GAAALDH1A1 | |
| SCHEMBL3129785 | 0.77 | PDK1 (0.67) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL359513 | 0.77 | NAMPT (0.46) | — | |
| SCHEMBL11088061 | 0.77 | RAB9A (0.58) | NPSR1CYP3A4GAAALDH1A1 | |
| SCHEMBL2531539 | 0.76 | EPHX2 (0.41) | GAA | |
| SCHEMBL746119 | 0.75 | ALDH1A1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | PDK1 3830/4885PDK2 1952/4885PDK3 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.